Oncology studies often have unique qualities that complicate budgeting and forecasting. Modelling various patient cohorts, complex treatments, adaptive trial designs, and timing the enrollment and costing of the study can be tricky, at best.
Learn some of the top considerations for budgeting oncology studies and tips for how to approach these challenges from our panel of biopharmaceutical professionals. We will discuss topics such as options to react more quickly to protocol amendments, planning for study extensions, and utilizing benchmarks to ensure you get competitive market pricing for outsourced services and their experiences of using various tactics and tools.
Help to improve your organizationâs oncology trial agility by implementing accurate budgeting and planning with speed and learning from these real-world examples.

Strengthen your processes and increase data-driven decision-making for faster study start-ups.
Strengthen your processes and increase data-driven decision-making for faster study start-ups.
RESOURCES
Explore Expert Insights and Resources for Clinical Excellence

Webinars
Join Strategikon CEO Anca Copaescu and Andrei Antonescu, Head of Product for a high-impact session exploring how Artificial Intelligence (AI) is transforming clinical outsourcing and vendor management in the pharmaceutical industry. While AI has rapidly advanced in areas like patient recruitment and drug discovery, clinical business operations have laggedâuntil now.

Blogs
Effective vendor governance is essential to ensure operational success, cost efficiency, and regulatory compliance. Learn more here in our blog!

Case Studies
Faced with inefficiencies, compliance risks, and fragmented communication, a biopharma company dramatically enhanced its vendor governance by implementing VISION!
DEMO
Request a demo
Discover how Strategikonâs advanced solutions can streamline your clinical trial operations. Request a personalized demo to explore how our tools transform budgeting, vendor management, and outsourcing efficiency for pharma and biotech.